The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis
Abstract
A major shift in our understanding of the membranoproliferative glomerulonephritis (MPGN) lesion is the focus on which components of the complement pathway are involved in mediating renal injury. Hence, MPGN is no longer classified solely by ultrastructural findings on biopsy but instead divided into immune complex-mediated lesions versus complement-mediated lesions. This emphasis on complement, in turn, leads to interest in therapies that target complement as potential disease-modifying agents. Eculizumab, the first available anticomplement therapy, blocks at the level of C5 and has revolutionized the treatment of complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Whether this agent will work equally well for the far more heterogeneous complement-mediated MPGN lesions, also known as C3 glomerulopathy, remains unclear. To date, the experience and published data on using eculizumab in MPGN suggests this agent will work for some, but not all, patients with this pathologic lesion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Cited by
C3 glomerulopathy: consensus report
Pickering, M. C., D'Agati, V. D., Nester, C. M., Smith, R. J., Haas, M., Appel, G. B., Alpers, C. E., Bajema, I. M., Bedrosian, C., Braun, M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.377 · Cited by 653
Leung, N., Bridoux, F., Batuman, V., Chaidos, A., Cockwell, P., D’Agati, V. D., Dispenzieri, A., Fervenza, F. C., Fermand, J.-P., Gibbs, S., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0077-4 · Cited by 551
C3 glomerulopathy — understanding a rare complement-driven renal disease
Smith, R. J. H., Appel, G. B., Blom, A. M., Cook, H. T., D’Agati, V. D., Fakhouri, F., Fremeaux-Bacchi, V., Józsi, M., Kavanagh, D., Lambris, J. D., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0107-2 · Cited by 409
Sethi, S., Haas, M., Markowitz, G. S., D’Agati, V. D., Rennke, H. G., Jennette, J. C., Bajema, I. M., Alpers, C. E., Chang, A., Cornell, L. D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060612 · Cited by 316
Molecules Great and Small: The Complement System
Mathern, D. R., & Heeger, P. S. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06230614 · Cited by 290
Metadata
- Authors
- Bomback, A. S.
- Venue
- Nephron Clinical Practice
- Publisher
- S. Karger AG
- Published
- 2014-11-11
- Volume
- 128
- Issue
- 3-4
- Pages
- 270-276
- ISSN
- 1660-2110 (ISSN-L)
- OpenAlex
- W2081522308
- Cited by
- 216
- References
- 1
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.